Oscar Marchetti

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


143 publications

2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
2024
Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS).
Couchepin J., Reinhold I., Kronig I., Guidi M., Buclin T., Schreiber P.W., Neofytos D., Lamoth F., Fungal Infection Network of Switzerland (FUNGINOS), 2024/05. Open forum infectious diseases, 11 (5) pp. ofae223. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7689B1E13106]
Serial monitoring of pancreatic stone protein for the detection of sepsis in intensive care unit patients with complicated abdominal surgery: A prospective, longitudinal cohort study.
Filippidis P., Hovius L., Tissot F., Orasch C., Flückiger U., Siegemund M., Pagani J.L., Eggimann P., Marchetti O., Lamoth F. et al., 2024/03/11. Journal of critical care, 82 p. 154772. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BB2800A65195]
2023
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
Maertens J., Lodewyck T., Donnelly J.P., Chantepie S., Robin C., Blijlevens N., Turlure P., Selleslag D., Baron F., Aoun M. et al., 2023/02/18. Clinical infectious diseases, 76 (4) pp. 674-682. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E34CCCFF4BB8]
SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection.
Jacot D., von Rotz U., Pellaton C., Blondet F., Aebischer O., Perreau M., De Rham M., Pantaleo G., Marchetti O., Greub G., 2023. Microbes and infection, 25 (1-2) p. 105077. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_35EA6DCB0511]
2022
 
Corrigendum to "Validation and clinical application of a multiplex high performance liquid chromatography - Tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections" [J. Chromatogr. B 1157 (2020) 122160].
Decosterd L.A., Mercier T., Ternon B., Cruchon S., Guignard N., Lahrichi S., Pesse B., Rochat B., Burger R., Lamoth F. et al., 2022/11/15..
[DOI][WoS][Pmid][serval:BIB_D81DA54DDABE]
A first update on mapping the human genetic architecture of COVID-19
Pathak G. A., Polimanti R., Karjalainen J., Daly M., Ganna A., Daly M. J., Stevens C., Kanai M., Liao R. G., Trankiem A. et al., 2022/08. Nature, 608 (7921) pp. E1-E10. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_381F39EA3F76]
 
SARS-CoV-2 seroprevalence in hospital healthcare workers in Western Switzerland at the end of the second pandemic wave.
Jacot D., von Rotz U., Blondet F., Aebischer O., Matthieu P., De Rham M., Pantaleo G., Marchetti O., Greub G., 2022/08. Journal of medical microbiology, 71 (8). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2E339D4530BF]
 
Correction to: Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031).
Cornely O.A., Gachot B., Akan H., Bassetti M., Uzun O., Kibbler C., Marchetti O., de Burghgraeve P., Ramadan S., Pylkkanen L. et al., 2022/05/30. Clinical infectious diseases, 74 (10) p. 1892. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2135191D79E4]
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
Dao K., Fuchs A., André P., Giannoni E., Decosterd L.A., Marchetti O., Asner S.A., Pfister M., Widmer N., Buclin T. et al., 2022/02/02. The Journal of Antimicrobial Chemotherapy, 77 (2) pp. 457-465. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6EBEF14704F8]
Maladies infectieuses - Acquis, nouveautés et perspectives en 2021 [Infectious diseases: Achievements, new Developments and Perspectives in 2021]
Blondet F., Aebischer O., Tusgul S., Monsalve Arteaga L., Schaad N., Challet C., Doser N., Sedda A., Urbano L., Marchetti O., 2022/02/02. Revue medicale suisse, 18 (767) pp. 173-181. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_2A7A2BCC8531]
2021
Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital.
Battistolo J., Glampedakis E., Damonti L., Poissy J., Grandbastien B., Kalbermatter L., Pagani J.L., Eggimann P., Bochud P.Y., Calandra T. et al., 2021/12. Mycoses, 64 (12) pp. 1512-1520. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_59B304F1CB77]
Mapping the human genetic architecture of COVID-19.
COVID-19 Host Genetics Initiative, Niemi M.E.K, 2021/12. Nature, 600 (7889) pp. 472-477. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_79689A554FE8]
Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey.
Adam K.M., Osthoff M., Lamoth F., Conen A., Erard V., Boggian K., Schreiber P.W., Zimmerli S., Bochud P.Y., Neofytos D. et al., 2021/10. Open forum infectious diseases, 8 (10) pp. ofab471. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E1C2CA5BE723]
The dark side of SARS-CoV-2 rapid antigen testing: screening asymptomatic patients.
Caruana G., Lebrun L.L., Aebischer O., Opota O., Urbano L., de Rham M., Marchetti O., Greub G., 2021/07. New microbes and new infections, 42 p. 100899. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B2C6AA99CFBC]
Médecine interne hospitalière dans un hôpital régional : enjeux du présent et défis pour le futur.
Marchetti O., Sedda A., Aebischer O., Blondet F., Tusgul S., Doser N., Urbano L., 2021/06/30. Revue medicale suisse, 17 (744-2) pp. 1279-1281. Peer-reviewed.
[URN][Pmid][serval:BIB_51647CFE4066]
 
Humeral periosteal spur sign with osteolysis as an early radiographic indicator of low-grade Cutibacterium acnes prosthetic shoulder infection.
Bauer S., Dietz B., Trampuz A., Marchetti O., 2021/03/25. BMJ case reports, 14 (3). Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AD957464EA16]
 
Assessment of the Role of 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults.
Lamoth F., Akan H., Andes D., Cruciani M., Marchetti O., Ostrosky-Zeichner L., Racil Z., Clancy C.J., 2021/03/12. Clinical infectious diseases, 72 (Suppl 2) pp. S102-S108. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_309237C62F3D]
 
Nosocomial influenza in south-western Swiss hospitals during two seasonal epidemics: an observational study.
Qalla-Widmer L., Héquet D., Troillet N., Petignat C., Balmelli C., Bassi C., Bellini C., Chave J.P., Cometta A., Christin L. et al., 2021/03. The Journal of hospital infection, 109 pp. 115-122. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F9C1B5F75342]
2020
Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
Decosterd L.A., Mercier T., Ternon B., Cruchon S., Guignard N., Lahrichi S., Pesse B., Rochat B., Burger R., Lamoth F. et al., 2020/11/10. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1157 p. 122160. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2ABB9B287690]
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
Donnelly J Peter, Chen Sharon C, Kauffman Carol A, Steinbach William J, Baddley John W, Verweij Paul E, Clancy Cornelius J, Wingard John R, Lockhart Shawn R, Groll Andreas H et al., 2020/09/12. Clinical Infectious Diseases, 71 (6) pp. 1367-1376. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6E65A6649EFA]
Risk factors for candidemia: a prospective matched case-control study.
Poissy J., Damonti L., Bignon A., Khanna N., Von Kietzell M., Boggian K., Neofytos D., Vuotto F., Coiteux V., Artru F. et al., 2020/03/18. Critical care, 24 (1) p. 109. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A42B1C805146]
Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis.
Lamoth F., Clancy C.J., Tissot F., Squires K., Eggimann P., Flückiger U., Siegemund M., Orasch C., Zimmerli S., Calandra T. et al., 2020/03. Open forum infectious diseases, 7 (3) pp. ofaa075. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_55AFFF4235BB]
2018
 
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R., Guidi M., Calpini V., Lamoth F., Decosterd L., Robatel C., Buclin T., Csajka C., Marchetti O., 2018/12/01. The Journal of antimicrobial chemotherapy, 73 (12) pp. 3413-3422. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C826664F7442]
 
Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Kritikos A., Neofytos D., Khanna N., Schreiber P.W., Boggian K., Bille J., Schrenzel J., Mühlethaler K., Zbinden R., Bruderer T. et al., 2018/11. Clinical microbiology and infection, 24 (11) pp. 1214.e1-1214.e4. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CDB7569EE916]
 
Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy.
Brunel A.S., Wójtowicz A., Lamoth F., Spertini O., Neofytos D., Calandra T., Marchetti O., Bochud P.Y., 2018/11. Haematologica, 103 (11) pp. e527-e530. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_57E679722B16]
 
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia
Maertens Johan A, Girmenia Corrado, Brüggemann Roger J, Duarte Rafael F, Kibbler Christopher C, Ljungman Per, Racil Zdeněk, Ribaud Patricia, Slavin Monica A, Cornely Oliver A et al., 2018/08/01. Journal of Antimicrobial Chemotherapy.
[DOI][WoS][Pmid][serval:BIB_9D3816476E6A]
 
Re: "Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network metaanalysis" by Horita et al.
Averbuch D., Orasch C., Mikulska M., Livermore D.M., Viscoli C., Gyssens I.C., Kern W.V., Klyasova G., Marchetti O., Engelhard D. et al., 2018/06. Clinical microbiology and infection, 24 (6) pp. 662-663. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_007FBEB58267]
 
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
Ullmann A.J., Aguado J.M., Arikan-Akdagli S., Denning D.W., Groll A.H., Lagrou K., Lass-Flörl C., Lewis R.E., Munoz P., Verweij P.E. et al., 2018/05. Clinical microbiology and infection, 24 Suppl 1 pp. e1-e38. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C63D7082A6A5]
 
Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study.
Orasch C., Mertz D., Garbino J., van Delden C., Emonet S., Schrenzel J., Zimmerli S., Damonti L., Mühlethaler K., Imhof A. et al., 2018/05. The Journal of infection, 76 (5) pp. 489-495. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AB78279BDFD7]
 
Correction to: Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia.
Damonti L., Erard V., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., Imhof A., Zbinden R., Fehr J., Boggian K. et al., 2018/03..
[DOI][WoS][Pmid][serval:BIB_57775AC05AC1]
2017
 
Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia.
Damonti L., Erard V., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., Imhof A., Zbinden R., Fehr J., Boggian K. et al., 2017/06. Intensive care medicine, 43 (6) pp. 935-939. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8C5A7EF6C586]
2016
 
Association of lectin pathway proteins with intra-abdominal Candida infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland.
Osthoff M., Wojtowicz A., Tissot F., Jørgensen C., Thiel S., Zimmerli S., Marchetti O., Khanna N., Bochud P.Y., Trendelenburg M. et al., 2016. Journal of Infection, 72 (3) pp. 377-385. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_45733C41DBF6]
 
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.
Maertens J., Cesaro S., Maschmeyer G., Einsele H., Donnelly J.P., Alanio A., Hauser P.M., Lagrou K., Melchers W.J., Helweg-Larsen J. et al., 2016. Journal of Antimicrobial Chemotherapy, 71 (9) pp. 2397-2404. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6CC4A69B8A68]
 
ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.
Alanio A., Hauser P.M., Lagrou K., Melchers W.J., Helweg-Larsen J., Matos O., Cesaro S., Maschmeyer G., Einsele H., Donnelly J.P. et al., 2016. Journal of Antimicrobial Chemotherapy, 71 (9) pp. 2386-2396. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D538B3877898]
 
Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients.
Cordonnier C., Cesaro S., Maschmeyer G., Einsele H., Donnelly J.P., Alanio A., Hauser P.M., Lagrou K., Melchers W.J., Helweg-Larsen J. et al., 2016. Journal of Antimicrobial Chemotherapy, 71 (9) pp. 2379-2385. Peer-reviewed.
[DOI][Pmid][serval:BIB_687A58D266A8]
2015
Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.
Asner S.A., Giulieri S., Diezi M., Marchetti O., Sanglard D., 2015/12. Antimicrobial agents and chemotherapy, 59 (12) pp. 7715-7722. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2355233CE663]
 
Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical.
Orasch C., Averbuch D., Mikulska M., Cordonnier C., Livermore D.M., Gyssens I.C., Klyasova G., Engelhard D., Kern W., Viscoli C. et al., 2015/03. Clinical microbiology and infection, 21 (3) pp. e25-7. Peer-reviewed.
[DOI][Pmid][serval:BIB_79E8BD59ECDD]
Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.
Herbrecht R., Patterson T.F., Slavin M.A., Marchetti O., Maertens J., Johnson E.M., Schlamm H.T., Donnelly J.P., Pappas P.G., 2015. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 60 (5) pp. 713-720. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_790D19DC85DC]
 
CSF lactate for accurate diagnosis of community-acquired bacterial meningitis.
Giulieri S., Chapuis-Taillard C., Jaton K., Cometta A., Chuard C., Hugli O., Du Pasquier R., Bille J., Meylan P., Manuel O. et al., 2015. European Journal of Clinical Microbiology and Infectious Diseases : Official Publication of the European Society of Clinical Microbiology, 34 (10) pp. 2049-2055. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_16CC808BB9C2]
 
Effective Treatment of Invasive Aspergillus fumigatus Infection Using Combinations of Topical and Systemic Antifungals in a Severely Burned Patient.
Fournier A., Pantet O., Guerid S., Eggimann P., Pagani J.L., Revelly J.P., Hauser P.M., Marchetti O., Fontanella S., Letovanec I. et al., 2015. Journal of Burn Care and Research, 36 (2) pp. e85-e89. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7801E93C98E1]
Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031).
Cornely O.A., Gachot B., Akan H., Bassetti M., Uzun O., Kibbler C., Marchetti O., de Burghgraeve P., Ramadan S., Pylkkanen L. et al., 2015. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 61 (3) pp. 324-331. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_46F4D73EE4C7]
 
Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
Fournier A., Eggimann P., Pagani J.L., Revelly J.P., Decosterd L.A., Marchetti O., Pannatier A., Voirol P., Que Y.A., 2015. Burns, 41 (5) pp. 956-968. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_250BAF754387]
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. pp. Abstr. 3505 dans 24th Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[serval:BIB_08604FD033C0]
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. dans Nano-Tera Annual Plenary Meeting.
[serval:BIB_D01690AA9CCD]
 
Rapid detection of enterovirus in cerebrospinal fluid by a fully-automated PCR assay is associated with improved management of aseptic meningitis in adult patients.
Giulieri S.G., Chapuis-Taillard C., Manuel O., Hugli O., Pinget C., Wasserfallen J.B., Sahli R., Jaton K., Marchetti O., Meylan P., 2015. Journal of Clinical Virology, 62 pp. 58-62.
[DOI][WoS][Pmid][serval:BIB_1D101BF524FB]
2014
 
Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Orasch C., Marchetti O., Garbino J., Schrenzel J., Zimmerli S., Mühlethaler K., Pfyffer G., Ruef C., Fehr J., Zbinden R. et al., 2014/07. Clinical microbiology and infection, 20 (7) pp. 698-705. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E67E241BAEB4]
 
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.
Groll A.H., Castagnola E., Cesaro S., Dalle J.H., Engelhard D., Hope W., Roilides E., Styczynski J., Warris A., Lehrnbecher T. et al., 2014. Lancet. Oncology, 15 (8) pp. e327-e340. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_63FCC0B27D4C]
 
High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.
Mercier T., Tissot F., Gardiol C., Corti N., Wehrli S., Guidi M., Csajka C., Buclin T., Couet W., Marchetti O. et al., 2014. Journal of Chromatography. A, 1369 pp. 52-63. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0D0099C7E204]
 
Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia.
Kumar V., Cheng S.C., Johnson M.D., Smeekens S.P., Wojtowicz A., Giamarellos-Bourboulis E., Karjalainen J., Franke L., Withoff S., Plantinga T.S. et al., 2014. Nature Communications, 5 p. 4675. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_077582CC14B8]
 
Polymorphisms in tumor necrosis factor-α increase susceptibility to intra-abdominal Candida infection in high-risk surgical ICU patients*.
Wójtowicz A., Tissot F., Lamoth F., Orasch C., Eggimann P., Siegemund M., Zimmerli S., Flueckiger U.M., Bille J., Calandra T. et al., 2014. Critical Care Medicine, 42 (4) pp. e304-e308. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9E94BE692A2A]
2013
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.
Averbuch D., Orasch C., Cordonnier C., Livermore D.M., Mikulska M., Viscoli C., Gyssens I.C., Kern W.V., Klyasova G., Marchetti O. et al., 2013. Haematologica, 98 (12) pp. 1826-1835.
[URN][DOI][WoS][Pmid][serval:BIB_3D5AD3939EF5]
 
Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy--EORTC Infectious Diseases Group Trial XV.
Kern W.V., Marchetti O., Drgona L., Akan H., Aoun M., Akova M., de Bock R., Paesmans M., Viscoli C., Calandra T., 2013. Journal of Clinical Oncology, 31 (9) pp. 1149-1156.
[DOI][WoS][Pmid][serval:BIB_81D0FA1259FB]
 
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).
Averbuch D., Cordonnier C., Livermore D.M., Mikulska M., Orasch C., Viscoli C., Gyssens I.C., Kern W.V., Klyasova G., Marchetti O. et al., 2013. Haematologica, 98 (12) pp. 1836-1847.
[DOI][WoS][Pmid][serval:BIB_FA1EDD167A59]
 
β-Glucan Antigenemia Anticipates Diagnosis of Blood Culture-Negative Intraabdominal Candidiasis.
Tissot F., Lamoth F., Hauser P.M., Orasch C., Flückiger U., Siegemund M., Zimmerli S., Calandra T., Bille J., Eggimann P. et al., 2013. American Journal of Respiratory and Critical Care Medicine, 188 (9) pp. 1100-1109.
[DOI][WoS][Pmid][serval:BIB_5D0AA27187E7]
2012
 
ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients.
Marchetti O., Lamoth F., Mikulska M., Viscoli C., Verweij P., Bretagne S., European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups, 2012/06. Bone marrow transplantation, 47 (6) pp. 846-854. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E84C3E2378D6]
Voriconazole-induced periostitis.
Rossier C., Dunet V., Tissot F., Aubry-Rozier B., Marchetti O., Boubaker A., 2012/02. European journal of nuclear medicine and molecular imaging, 39 (2) pp. 375-376. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_686C121C4DA5]
 
Agents anti-infectieux et fonction réna!e: vers des posologies sur mesure [Antimicrobial agents and renal elimination: towards individual dosage adjustment?].
Willi-Robatel C., Senn L., Livio F., Zanetti G., Marchetti O., Buclin T., 2012. Revue Médicale Suisse, 8 (338) pp. 894-900.
[Pmid][serval:BIB_DD6FE1F6DCBC]
 
Antimicrobial Agents
Csajka C., Marchetti O., Manuel O., Decosterd L., Telenti A., 2012. pp. 379-402 dans Anzenbacher P., Zanger U.M. (eds.) Metabolism of Drugs and Other Xenobiotics chap. 14, Wiley-VCH Verlag.
[DOI][serval:BIB_12273AD3B89C]
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A., Csajka C., Buclin T., Bolay S., Bille J., Calandra T., Marchetti O., 2012. Clinical Infectious Diseases, 55 (3) pp. 381-390.
[URN][DOI][WoS][Pmid][serval:BIB_0A1C9377388D]
 
Invasive Candida infections in the ICU
Eggimann P., Barberini L., Calandra T., Marchetti O., 2012. Mycoses, 55 (Suppl. 1) pp. 65-72. Peer-reviewed.
[DOI][WoS][serval:BIB_9B179B33AC10]
 
Response to: lack of intra-laboratory reproducibility in using Platelia Aspergillus enzyme immunoassay test for detection of Aspergillus galactomannan antigen.
Bizzini A., Marchetti O., Meylan P., 2012. Transplant Infectious Disease, 14 (2) pp. 218-219.
[DOI][WoS][Pmid][serval:BIB_02CEF517C555]
β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3).
Lamoth F., Cruciani M., Mengoli C., Castagnola E., Lortholary O., Richardson M., Marchetti O., Third European Conference on Infections in Leukemia (ECIL-3), 2012. Clinical Infectious Diseases, 54 (5) pp. 633-643.
[URN][DOI][WoS][Pmid][serval:BIB_0B86B0DE8874]
2011
 
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update.
Maertens J., Marchetti O., Herbrecht R., Cornely O.A., Flückiger U., Frêre P., Gachot B., Heinz W.J., Lass-Flörl C., Ribaud P. et al., 2011/05. Bone marrow transplantation, 46 (5) pp. 709-718. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CFF49E451D67]
Diagnosis of invasive candidiasis in the ICU.
Eggimann P., Bille J., Marchetti O., 2011. Annals of Intensive Care, 1 p. 37. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9E2018780C4A]
Is (1→3)-β-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis?
Eggimann P., Marchetti O., 2011. Critical Care, 15 (6) p. 1017. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2A718AF5A7D8]
Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent Fever?
Robinson J.O., Lamoth F., Bally F., Knaup M., Calandra T., Marchetti O., 2011. Plos One, 6 (4) pp. e18886.
[URN][DOI][WoS][Pmid][serval:BIB_8777D1F23997]
 
Prolonged fluconazole exposure leads to a shift to Candida species with decreased susceptibility in breakthrough candidemia: prospective survey of the Fungal Infection Network of Switzerland
Orasch C. E., Marchetti O., Bille J., 2011. pp. 59-60 dans 5th Congress on Trends in Medical Mycology, Mycoses. Peer-reviewed.
[WoS][serval:BIB_E41E6AEC1EA4]
Treatment and timing in invasive mould disease.
Maertens J., Groll A.H., Cordonnier C., de la Cámara R., Roilides E., Marchetti O., 2011. Journal of Antimicrobial Chemotherapy, 66 (Suppl 1) pp. i37-i43.
[URN][DOI][WoS][Pmid][serval:BIB_92AEB095500C]
 
Utility of beta-glucan for the diagnosis of invasive fungal infections
Marchetti O., 2011. p. 46 dans 5th Congress on Trends in Medical Mycology, Mycoses. Peer-reviewed.
[WoS][serval:BIB_901B90684AD3]
2010
 
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
Herbrecht R., Maertens J., Baila L., Aoun M., Heinz W., Martino R., Schwartz S., Ullmann A.J., Meert L., Paesmans M. et al., 2010. Bone Marrow Transplantation, 45 (7) pp. 1227-1233.
[DOI][WoS][Pmid][serval:BIB_E8DCDBA6F74E]
 
High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.
Lamoth F., Buclin T., Pascual A., Vora S., Bolay S., Decosterd L.A., Calandra T., Marchetti O., 2010. Antimicrobial Agents and Chemotherapy, 54 (10) pp. 4360-4367.
[DOI][WoS][Pmid][serval:BIB_5A96268D6970]
 
Infections in the cancer patient. Section 4 (Infections in the immunocompromised host 79)
O. Marchetti T. Calandra., 2010. dans Infectious Diseases, 4rd Edition, 2010, Edited by J Cohen, WG Powderly. Elsevier Science.
[serval:BIB_6090F4D58079]
 
Infections in the neutropenic cancer patient
Marchetti O., Calandra T., 2010. pp. 804-820 dans Cohen J., Opal S.M., Powderly W.G. (eds.) Infectious Diseases chap. 73, Mosby.
[serval:BIB_015AD4102929]
 
Infections in the neutropenic cancer patient. Section 4 (Infections in the immunocompromised host)
Marchetti O., Calandra T., 2010. pp. 804-820 dans Infectious Diseases chap. 73, Mosby.
[serval:BIB_792100E5BA7B]
 
Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome?
Marchetti Oscar, Eggimann Philippe, Calandra Thierry, 2010. Current Opinion In Critical Care, 16 (5) pp. 442-444.
[DOI][WoS][Pmid][serval:BIB_C52312385096]
 
Monitoring of 1,3-Beta-D-Glucan in High-Risk Surgical ICU Patients for Early Diagnosis of Invasive Candidiasis: a Prospective Study of the Swiss Fungal Infection Network (FUNGINOS)
Tissot F., Lamoth F., Eggiman P., Bille J., Hauser P., Fluckiger U., Siegemund M., Orasch C., Zimmerli S., Calandra T. et al., 2010. dans 50th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
[serval:BIB_E0EA35928242]
 
Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia.
Lamoth F., Jaton K., Prod'hom G., Senn L., Bille J., Calandra T., Marchetti O., 2010. Journal of Clinical Microbiology, 48 (10) pp. 3510-3516.
[DOI][WoS][Pmid][serval:BIB_A64C6B86455E]
 
Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.
Decosterd L.A., Rochat B., Pesse B., Mercier T., Tissot F., Widmer N., Bille J., Calandra T., Zanolari B., Marchetti O., 2010. Antimicrobial Agents and Chemotherapy, 54 (12) pp. 5303-5315. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0E97FEBE3245]
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia.
Mikulska M., Calandra T., Sanguinetti M., Poulain D., Viscoli C., Third European Conference on Infections in Leukemia Group, 2010. Critical Care, 14 (6) pp. R222.
[URN][DOI][WoS][Pmid][serval:BIB_059C5E3D1FD5]
 
Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.
Rochat B., Pascual A., Pesse B., Lamoth F., Sanglard D., Decosterd L.A., Bille J., Marchetti O., 2010. Antimicrobial Agents and Chemotherapy, 54 (12) pp. 5074-5081.
[DOI][WoS][Pmid][serval:BIB_F9010791A938]
2009
An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
Viscoli C., Herbrecht R., Akan H., Baila L., Sonet A., Gallamini A., Giagounidis A., Marchetti O., Martino R., Meert L. et al., 2009. Journal of Antimicrobial Chemotherapy, 64 (6) pp. 1274-1281.
[URN][DOI][WoS][Pmid][serval:BIB_C47DE3F32CE4]
 
Antifungal therapeutic drug monitoring: established and emerging indications.
Andes D., Pascual A., Marchetti O., 2009. Antimicrobial Agents and Chemotherapy, 53 (1) pp. 24-34. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A91EFAF8CA67]
Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients.
Senn L., Eggimann P., Ksontini R., Pascual A., Demartines N., Bille J., Calandra T., Marchetti O., 2009. Intensive Care Medicine, 35 (5) pp. 903-908. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C56A3484A9F2]
 
High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction.
Lamoth F., Erard V., Asner S., Buclin T., Calandra T., Marchetti O., 2009. International Journal of Antimicrobial Agents, 34 (4) pp. 386-388.
[DOI][WoS][Pmid][serval:BIB_E23443E778F9]
Imipenem underdosing as a cause of persistent neutropenic fever?
Lamoth F., Buclin T., Pascual A., Calandra T., Marchetti O., 2009. Journal of Antimicrobial Chemotherapy, 64 (3) pp. 665-667.
[URN][DOI][WoS][Pmid][serval:BIB_8C7E736FBB7C]
 
New developments and challenges in diagnostics of invasive mycoses : W01.2
Marchetti O., 2009. p. 3 dans Abstracts of the 4th Trends in Medical Mycology, Mycoses. Peer-reviewed.
[WoS][serval:BIB_E3F966FEC180]
On track to limit antifungal overuse!
Eggimann P., Lamoth F., Marchetti O., 2009. Intensive Care Medicine, 35 (4) pp. 582-584. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0D6C7E366DF5]
 
Pulmonary lesions as first computed-tomography presentation of invasive candidiasis in neutropenic patients : P067
Tissot F., Lamoth F.L., Schmidt S.S., Senn L.S., Erard V.E., Bille J.B., Duvoisin B.D., Calandra T.C., Marchetti O.M., 2009. p. 52 dans Abstracts of the 4th Trends in Medical Mycology, Mycoses. Peer-reviewed.
[WoS][serval:BIB_886360EA7A91]
 
Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
Lamoth F., Buclin T., Csajka C., Pascual A., Calandra T., Marchetti O., 2009. Antimicrobial Agents and Chemotherapy, 53 (2) pp. 785-787. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3C81678B0325]
2008
1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia.
Senn L., Robinson J.O., Schmidt S., Knaup M., Asahi N., Satomura S., Matsuura S., Duvoisin B., Bille J., Calandra T. et al., 2008/03. Clinical Infectious Diseases, 46 (6) pp. 878-885. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C3751492AAD0]
 
Antibiothérapie empirique lors de neutropénie fébrile [Empirical antibiotic therapy for febrile neutropenia]
Kridel R., Van Delden C., Calandra T., Marchetti O., 2008. Revue Médicale Suisse, 4 (152) pp. 914-919.
[Pmid][serval:BIB_7CC682F92B4B]
Bench-to-bedside review: Candida infections in the intensive care unit.
Méan M., Marchetti O., Calandra T., 2008. Critical Care, 12 (1) p. 204.
[URN][DOI][WoS][Pmid][serval:BIB_66EF3F7596AC]
 
beta-glucan in the diagnosis of invasive fungal disease - Reply
Senn L, Calandra T, Bille J, Marchetti O, 2008. CLINICAL INFECTIOUS DISEASES, 47 (2) pp. 293-294.
[WoS][serval:BIB_F41FF47044A4]
 
Beta-glucan in the diagnosis of invasive fungal disease : Reply letter to Pasqualotto and Sukiennik
Senn L., Calandra T., Bille J., Marchetti O., 2008. Clinical Infectious Diseases, 47 (2) pp. 293-294. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D49D0A1D0576]
 
Flash d'infeziologia : candidosi orofaringea
Marchetti O., Mombelli G., 2008. Tribuna Medica Ticinese 73 pp. 229-232.
[serval:BIB_72673FAFB00E]
Reply to Pasqualotto and Sukiennik
Senn L., Calandra T., Bille J., Marchetti O., 2008. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 47 (2) pp. 293-294.
[URN][DOI][WoS][Pmid][serval:BIB_CD631B981C57]
 
Revidierte schweizerische Richtlinien für die Endokarditis Prophylaxe
Fluckiger U., Jaussi A., 2008. Kardiovaskuläre Medizin, 11 (12) pp. 392-400.
[serval:BIB_6F6FF31901FC]
 
Septifast PCR for the microbiological documentation of infections in febrile neutropenic patients
Lamoth Frederic, Jaton-Ogay Katia, Calandra Thierry, Prodhom G.u.y., Senn Laurence, Bille Jacques, Marchetti Oscar, 2008. pp. S31-S32 dans Abstracts of the 15th International Symposium on Infections in the Immunocompromised Host, International Journal of Infectious Diseases. Peer-reviewed.
[DOI][WoS][serval:BIB_BBDCDE156E1D]
 
Suivi thérapeutique des médicaments (II). La pratique clinique [Therapeutic drug monitoring: clinical practice].
Widmer N., Werner D., Grouzmann E., Eap C.B., Marchetti O., Fayet A., Csajka C., Decosterd L.A., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1649-1660. Peer-reviewed.
[Pmid][serval:BIB_53F56A1C36B3]
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O., 2008. Clinical Infectious Diseases, 46 (2) pp. 201-211.
[URN][DOI][WoS][Pmid][serval:BIB_0AF2ACCE09D5]
2007
Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy
Vekemans M., Robinson J., Georgala A., Heymans C., Muanza F., Paesmans M., Klastersky J., Barette M., Meuleman N., Huet F. et al., 2007/06. Clinical Infectious Diseases, 44 (12) pp. 1593-601.
[URN][DOI][WoS][Pmid][serval:BIB_073D784CC5C4]
 
Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples
Rochat B., Bolay S., Pascual A., Calandra T., Marchetti O., 2007/04. Journal of Mass Spectrometry, 42 (4) pp. 440-9.
[DOI][WoS][Pmid][serval:BIB_8627F3703736]
 
Empirical antifungal therapy in neutropaenic cancer patients with persistent fever
Marchetti O., Cordonnier C., Calandra T., 2007. European Journal of Cancer. Supplement, 5 (2) pp. 32-42.
[DOI][WoS][serval:BIB_ACBE350E603C]
 
Empirical use of anti-Gram-positive antibiotics in febrile neutropaenic cancer patients with acute leukaemia
Cometta A., Marchetti O., Calandra T., 2007. European Journal of Cancer. Supplement, 5 (2) pp. 23-31.
[DOI][WoS][serval:BIB_D816F555A3A2]
 
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.
Pascual A., Nieth V., Calandra T., Bille J., Bolay S., Decosterd L.A., Buclin T., Majcherczyk P.A., Sanglard D., Marchetti O., 2007. Antimicrobial Agents and Chemotherapy, 51 (1) pp. 137-143.
[DOI][WoS][Pmid][serval:BIB_62560DA1D073]
2006
In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients
Cometta A., Marchetti O., Calandra T., Bille J., Kern W. V., Zinner S., 2006/08. European Journal of Clinical Microbiology and Infectious Diseases, 25 (8) pp. 537-40.
[URN][DOI][WoS][Pmid][serval:BIB_C7CA4544A058]
Treatment options of invasive fungal infections in adults.
Flückiger U., Marchetti O., Bille J., Eggimann P., Zimmerli S., Imhof A., Garbino J., Ruef C., Pittet D., Täuber M. et al., 2006/07/22. Swiss medical weekly, 136 (29-30) pp. 447-463. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_B671A5617F0E]
2005
 
Changing face of health-care associated fungal infections.
Bille J., Marchetti O., Calandra T., 2005/08. Current Opinion in Infectious Diseases, 18 (4) pp. 314-319. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F26B68B9E05F]
 
Necrose du segment anterieur sur keratomycose a Fusarium polyresistant. A propos d'un cas. [Anterior segment necrosis in multidrug-resistant Fusarium keratomycosis: a case study]
Gianoli F., Guex-Crosier Y., Marchetti O., Wolfensberger T. J., Spahn B., 2005/05. Journal Français d'Ophtalmologie, 28 (5) pp. 498-501.
[DOI][WoS][Pmid][serval:BIB_3322031439F8]
 
Utilite de la procalcitonine dans le diagnostic et le suivi des infections chez les patients neutropeniques febriles. [Utility of procalcitonin for the diagnosis and the follow-up of infections in febrile neutropenic patients]
Robinson J. O., Calandra T., Marchetti O., 2005/03. Revue Médicale Suisse, 1 (13) pp. 878-82, 885-6.
[Pmid][serval:BIB_6FD19B7CD714]
 
Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies.
Prella M., Bille J., Pugnale M., Duvoisin B., Cavassini M., Calandra T., Marchetti O., 2005. Diagnostic Microbiology and Infectious Disease, 51 (2) pp. 95-101. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_36702]
 
Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists.
Eggimann P., Calandra T., Fluckiger U., Bille J., Garbino J., Glauser M.P., Marchetti O., Ruef C., Täuber M., Pittet D., 2005. Intensive care medicine, 31 (11) pp. 1514-21. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A18308CBA34A]
2004
 
Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review
Bochud P. Y., Bonten M., Marchetti O., Calandra T., 2004/11. Critical Care Medicine, 32 (11 Suppl) pp. S495-512.
[Pmid][serval:BIB_E620137692A7]
Clinical trials of antifungal prophylaxis among patients undergoing surgery
Calandra T., Marchetti O., 2004/10. Clinical Infectious Diseases, 39 Suppl 4 pp. S185-92.
[URN][DOI][WoS][Pmid][serval:BIB_3DAF04C7A706]
Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient.
Robatel C., Rusca M., Padoin C., Marchetti O., Liaudet L., Buclin T., 2004/07. The Journal of Antimicrobial Chemotherapy, 54 (1) pp. 269-270. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7A37F4C59DB8]
Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000
Marchetti O., Bille J., Fluckiger U., Eggimann P., Ruef C., Garbino J., Calandra T., Glauser M. P., Tauber M. G., Pittet D., 2004/02. Clinical Infectious Diseases, 38 (3) pp. 311-20.
[URN][DOI][WoS][Pmid][serval:BIB_182048CCAD71]
 
Can we describe the epidemiology of candidemia without using selective blood culture bottles for fungus detection?
Tattevin P., Chevrier S., Gangneux J.P., 2004. Clinical Infectious Diseases, 39 (4) pp. 598-599; author reply 599.
[DOI][WoS][Pmid][serval:BIB_E1023B43F9D0]
 
Prise en charge ambulatoire des neutropénies fébriles à bas risque de complications: fiction ou réalité ?
Cometta A., Marchetti O., Bally F., Calandra T., 2004. Médecine et Hygiène, 62 (2479) pp. 855-60.
[serval:BIB_B385A99EB9E8]
Reply
Bille J., Marchetti O., Pittet D., 2004. Clinical Infectious Diseases, 39 (4) pp. 599-599.
[URN][DOI][WoS][serval:BIB_E3A1618C7B89]
 
Reply to the letter by Tattevin et al "Can we describe the epidemiology of candidemia without using selective blood culture bottles for fungus detections ? "
Bille J., Marchetti O., Pittet D., for the Fungal Infection Network of Switzerland, 2004. Clinical Infectious Diseases, 599 p. 39.
[serval:BIB_1547B2E9E6B1]
2003
 
Neutropenies febriles. [Febrile neutropenia]
Bally F., Marchetti O., Cometta A., 2003/12. Revue du Praticien, 53 (19) pp. 2101-7.
[Pmid][serval:BIB_BAFCE65D2BE1]
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy
Cometta A., Kern W. V., De Bock R., Paesmans M., Vandenbergh M., Crokaert F., Engelhard D., Marchetti O., Akan H., Skoutelis A. et al., 2003/08. Clinical Infectious Diseases, 37 (3) pp. 382-9.
[URN][DOI][WoS][Pmid][serval:BIB_330436096753]
 
Candida glabrata spinal osteomyelitis involving two contiguous lumbar vertebrae: a case report and review of the literature
Seravalli L., Van Linthoudt D., Bernet C., de Torrente A., Marchetti O., Porchet F., Genne D., 2003/02. Diagnostic Microbiology and Infectious Disease, 45 (2) pp. 137-41.
[DOI][WoS][Pmid][serval:BIB_CA1CEAABF534]
 
Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence.
Sanglard D., Ischer F., Marchetti O., Entenza J., Bille J., 2003. Molecular Microbiology, 48 (4) pp. 959-976.
[DOI][WoS][Pmid][serval:BIB_972BB8241B89]
 
Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes.
Marchetti O., Moreillon P., Entenza J.M., Vouillamoz J., Glauser M.P., Bille J., Sanglard D., 2003. Antimicrobial Agents and Chemotherapy, 47 (5) pp. 1565-1570.
[DOI][WoS][Pmid][serval:BIB_C1A5CCC317C2]
 
Infections in the neutropenic cancer patient
Marchetti O., Calandra T., 2003. 15.
[serval:BIB_2FB11EAC5310]
 
Infections in the neutropenic cancer patient. Section 4 (Infections in the immunocompromised host)
Marchetti O., 2003. pp. 1077-1092 dans Infectious Diseases chap. 102, Mosby.
[serval:BIB_14D344086507]
 
Prise en charge de la neutropénie fébrile à bas risque
Cometta A., Marchetti O., Calandra T., 2003. Swiss Medical Forum = Forum Médical Suisse, 3 (6) pp. 124-129.
[serval:BIB_0A2D5719712A]
Response to van Saene et al.'s comment on "Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients".
Calandra T., Marchetti O., 2003. Intensive care medicine, 29 (7) p. 1196. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B6AFD1B34148]
 
Traitement des infections invasives à Candida et Aspergillus : quoi de neuf en 2003 ?
Marchetti O., Calandra T., 2003. Médecine et Hygiène, 61 (2431) pp. 701-706.
[serval:BIB_62722B3B6C11]
2002
 
Disseminated histoplasmosis in Switzerland: an unexpected cause of septic shock and multiple organ dysfunction
Cavassini M., Lepori M., Baur A. S., Bille J., Schaller M. D., Marchetti O., 2002/10. Intensive Care Medicine, 28 (10) pp. 1501-2.
[DOI][WoS][Pmid][serval:BIB_435AF64EB12D]
 
Antifungal prophylaxis for intensive care unit patients: let's fine tune it.
Calandra T., Marchetti O., 2002. Intensive care medicine, 28 (12) pp. 1698-1700. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_44BFF3199418]
 
Infections in neutropenic cancer patients.
Marchetti O., Calandra T., 2002. Lancet, 359 (9308) pp. 723-725.
[DOI][WoS][Pmid][serval:BIB_689D0ED57B49]
 
Maladie de Weil: à propos d'un cas de leptospirose acquise en Suisse [Weil's disease: a case report of acquired leptospirosis in Switzerland].
Pantet O., Bonny O., Marchetti O., Prella M., 2002. Revue Médicale de la Suisse Romande, 122 (9) pp. 455-458.
[Pmid][serval:BIB_6EEAFD8B776D]
 
Single-step extraction of fluconazole from plasma by ultra-filtration for the measurement of its free concentration by high performance liquid chromatography.
Majcherczyk P.A., Moreillon P., Decosterd L.A., Sanglard D., Bille J., Glauser M.P., Marchetti O., 2002. Journal of Pharmaceutical and Biomedical Analysis, 28 (3-4) pp. 645-651.
[DOI][WoS][Pmid][serval:BIB_B7BF67540321]
2001
 
Prise en charge des neutropénies fébriles
Marchetti O., Bally F., Cometta A., 2001. Oncologie, 3 pp. 278-285.
[serval:BIB_3094DCCDEDBC]
 
Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles.
Marchetti O., Majcherczyk P.A., Glauser M.P., Bille J., Moreillon P., Sanglard D., 2001. Antimicrobial Agents and Chemotherapy, 45 (3) pp. 696-700.
[DOI][WoS][Pmid][serval:BIB_C57403C1A536]
2000
 
Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.
Marchetti O., Entenza J.M., Sanglard D., Bille J., Glauser M.P., Moreillon P., 2000. Antimicrobial Agents and Chemotherapy, 44 (11) pp. 2932-2938.
[DOI][WoS][Pmid][serval:BIB_6876CE78F3C0]
 
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.
Marchetti O., Moreillon P., Glauser M.P., Bille J., Sanglard D., 2000. Antimicrobial Agents and Chemotherapy, 44 (9) pp. 2373-2381.
[DOI][WoS][Pmid][serval:BIB_0C5FB7E5E8F7]
1999
 
Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis
Stricker H., Marchetti O., Haeberli A., Mombelli G., 1999/10. Thrombosis and Haemostasis, 82 (4) pp. 1227-31.
[WoS][Pmid][serval:BIB_ED12FEBD7C26]
1998
 
Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina
Mombelli G., Marchetti O., Haeberli A., Straub P. W., 1998/12. American Heart Journal, 136 (6) pp. 1106-13.
[WoS][Pmid][serval:BIB_C667EFFCA368]
 
Les infections à Candida aux soins intensifs
Marchetti O., Bille J., Glauser M. P., Calandra T., 1998. Médecine et hygiène, 56 (2207) pp. 942-946.
[serval:BIB_3BD4043F21E6]
 
Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.
Entenza J.M., Marchetti O., Glauser M.P., Moreillon P., 1998. Antimicrobial Agents and Chemotherapy, 42 (8) pp. 1889-1894.
[WoS][Pmid][serval:BIB_2694F5AB5897]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University